DAY 1 – November 11, 2009

SESSION I: Epigenetics – Its impact on Leukemia and Cancer Therapy – Jonathan Licht, MD, Moderator

8:00–8:20

Overview: History and Future of Differentiation Therapy

Samuel Waxman, MD

8:20–8:40

The History and Future of Demethylation Therapy

Peter A. Jones, PhD, DSc

8:40–9:00

Epigenetics and the Nuclear Receptors Epiegenetic Cancer Therapies

Jean-Pierre Issa, MD

9:00–9:20

Histone Methylation

Yang Shi, PhD

9:20–9:40

The Epigenetics of the Estrogen Receptor in Cancer

Myles A. Brown, MD

9:40–10:10

Discussion

10:10–10:30

Break

WORKSHOP: How do HDAC Inhibitors Work – Tomiki Naoe, MD, PhD, Moderator

10:30–10:50

Genetic Models to Elucidate HDAC Function

Ricky W. Johnstone, PhD

10:50–11:10

Vorinostat Mode of Action

Victoria M. Richon, PhD

11:10–11:30

Intelligent Use of HDAC Inhibitors and Combinations

Steven Grant, MD

11:30–11:50

HDAC-6 Inhibitors

James E. Bradner, MD

11:50–12:10

Discussion–HDAC inhibitors: What Are the Next Steps?

Arthur Z. Zelent, PhD, Tomoki Naoe, MD, PhD

12:10–12:40

Discussion

12:40–2:00

Lunch/Poster Walk

WORKSHOP: Mechanisms of Arsenic – Samuel Waxman, MD, Moderator

2:00–2:20

Arsenic and Reactive Oxygen Species

Wilson H. Miller Jr, MD, PhD

2:20–2:40

Proteomic and Genomic Effects of Arsenic

Sai-Juan Chen, MD

2:40–3:00

Novel Arsenic Combinations

Guo-Qiang Chen, MD, PhD

3:00–3:30

Discussion

3:30–3:50

Break

WORKSHOP: Epigenetic Clinical Trials – Steven D. Gore, MD, Moderator

3:50-4:10

Title TBD

H. Phillip Koeffler, MD

4:10-4:30

Azacitadine Combination Therapy

Steven D. Gore, MD

4:30-4:50

Decitabine with Valproic Acid and Other Combinations

Guido Marcucci, MD

4:50-5:10

Vorinostat and Combination Studies for MDS

TBD

5:10-5:30

Depsipeptide Clinical Trials

Susan E. Bates, MD

5:30-6:00

Discussion

Poster Session

Day 2 AgendaDay 3 AgendaDay 4 AgendaBack to Top